At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a
The team at Dana-Farber Cancer Institute is testing whether the combination of duvelisib (Copiktra™) and venetoclax (Venclexta®) will lead to deep remissions that would allow for oral only therapy of one year duration. Learn more about this ongoing Phase I/II clinical trial.
The treatment landscape for those of us with CLL/SLL has changed dramatically in the past decade or less. We see decreasing reliance on chemoimmunotherapies that were the only option in the past. We have seen a move from sequential use of targeted therapies to control our CLL to combinations
At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Paolo Ghia, Director of the Strategic Research Program on CLL at Università Vita-Salute San Raffaele in Milan, Italy. They discussed results from a clinical trial which individually tailored treatment plans
Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib have been wonderfully effective drugs for treating chronic lymphocytic leukemia (CLL). However, on their own they must be taken continuously and do not produce deep enough remissions to warrant stopping treatment.
Flow cytometry is the standard test to look for Measurable (Minimal) Residual Disease (MRD) in CLL and it can find one cancer cell in 10,000 by looking at the telltale combination of surface markers that are found on CLL cells but not on normal cells. Many labs can perform